Park Avenue Securities LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Park Avenue Securities LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 6,591 shares of the biopharmaceutical company’s stock, valued at approximately $261,000.

Several other large investors also recently bought and sold shares of the company. Assetmark Inc. grew its holdings in Halozyme Therapeutics by 1,067.4% in the third quarter. Assetmark Inc. now owns 25,450 shares of the biopharmaceutical company’s stock valued at $1,006,000 after purchasing an additional 23,270 shares during the last quarter. SG Americas Securities LLC grew its holdings in Halozyme Therapeutics by 66.6% in the third quarter. SG Americas Securities LLC now owns 66,233 shares of the biopharmaceutical company’s stock valued at $2,619,000 after purchasing an additional 26,479 shares during the last quarter. Comerica Bank grew its holdings in Halozyme Therapeutics by 2.1% in the third quarter. Comerica Bank now owns 64,525 shares of the biopharmaceutical company’s stock valued at $3,005,000 after purchasing an additional 1,333 shares during the last quarter. US Bancorp DE grew its holdings in Halozyme Therapeutics by 2.1% in the third quarter. US Bancorp DE now owns 11,305 shares of the biopharmaceutical company’s stock valued at $447,000 after purchasing an additional 236 shares during the last quarter. Finally, Synovus Financial Corp grew its holdings in Halozyme Therapeutics by 43.7% in the third quarter. Synovus Financial Corp now owns 76,918 shares of the biopharmaceutical company’s stock valued at $3,040,000 after purchasing an additional 23,393 shares during the last quarter. Institutional investors and hedge funds own 96.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on HALO shares. Benchmark increased their price objective on Halozyme Therapeutics from $55.00 to $68.00 and gave the company a “buy” rating in a research note on Thursday, December 8th. SVB Leerink decreased their price objective on Halozyme Therapeutics from $62.00 to $61.00 and set an “outperform” rating on the stock in a research note on Wednesday, January 11th. JMP Securities increased their price objective on Halozyme Therapeutics from $60.00 to $62.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 9th. Wells Fargo & Company started coverage on Halozyme Therapeutics in a research note on Monday, November 28th. They set an “overweight” rating and a $65.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $53.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 22nd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $59.63.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $51.42 on Tuesday. The stock’s 50-day moving average is $55.26 and its 200-day moving average is $48.34. The company has a market cap of $6.95 billion, a price-to-earnings ratio of 34.51, a price-to-earnings-growth ratio of 0.67 and a beta of 1.23. The company has a debt-to-equity ratio of 15.37, a current ratio of 5.97 and a quick ratio of 5.03. Halozyme Therapeutics, Inc. has a 12 month low of $31.36 and a 12 month high of $59.46.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last released its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.21. The company had revenue of $208.98 million for the quarter, compared to the consensus estimate of $187.87 million. Halozyme Therapeutics had a return on equity of 134.71% and a net margin of 36.37%. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 2.07 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $54.13, for a total value of $541,300.00. Following the transaction, the senior vice president now directly owns 163,137 shares in the company, valued at approximately $8,830,605.81. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $54.13, for a total transaction of $541,300.00. Following the sale, the senior vice president now directly owns 163,137 shares in the company, valued at approximately $8,830,605.81. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Nicole Labrosse sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $53.81, for a total value of $269,050.00. Following the sale, the chief financial officer now owns 4,045 shares in the company, valued at $217,661.45. The disclosure for this sale can be found here. Insiders have sold a total of 85,000 shares of company stock worth $4,666,350 in the last three months. 2.30% of the stock is currently owned by company insiders.

Halozyme Therapeutics Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Further Reading

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.